Designation of Andepatuzumab mafodotin (TBA) as an orphan drug - AbbVie Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the quality, safety, efficacy, and timely availability of therapeutic goods, including medicines, medical devices, and blood products. The Act establishes a framework for the approval, monitoring, and control of these goods, addressing issues related to public health and safety. One notable aspect of the Act is its provision for the designation of orphan drugs, which are medications intended for the treatment of rare diseases. The 1989 Act introduced this mechanism to incentivise the development and availability of treatments for conditions that affect a small proportion of the population, thereby addressing a significant gap in the therapeutic landscape. The designation of Andepatuzumab mafodotin (TBA) as an orphan drug under the Therapeutic Goods Regulations 1990, specifically for the treatment of glioblastoma multiforme, exemplifies the Act's policy objective to support the development of therapies for rare and life-threatening conditions.

Scope and Application

The Therapeutic Goods Act 1989, under the authority of the Therapeutic Goods Administration (TGA) in the Commonwealth of Australia, designates specific substances as therapeutic goods, including medicines, based on their potential to treat particular medical conditions. The Act applies to the regulation of therapeutic goods, encompassing entities such as pharmaceutical companies, medical practitioners, and consumers. In this instance, the Act designates Andepatuzumab mafodotin (TBA) as an orphan drug for the treatment of glioblastoma multiforme, indicating its relevance to medical treatment within Australia. The geographic reach of this Act is national, applying across the entirety of Australia. Notably, the Act extends its application through subordinate instruments, such as the Therapeutic Goods Regulations 1990, which provide further detail on the administration and control of therapeutic goods, including orphan drugs. The designation of Andepatuzumab mafodotin (TBA) as an orphan drug under this Act aims to facilitate the development and availability of treatments for rare diseases, in this case, glioblastoma multiforme, by offering certain incentives and regulatory support to the sponsor, AbbVie Pty Ltd.

Key Provisions

The Therapeutic Goods Act 1989, through this particular Gazette, designates Andepatuzumab mafodotin (TBA) as an orphan drug for the treatment of glioblastoma multiforme (section 16J of the Therapeutic Goods Regulations 1990). This specific designation, effective from 15 September 2016, acknowledges the drug's intended use in treating a rare disease, glioblastoma multiforme, and the form it takes for administration, which is a lyophilised powder for injection. The sponsor of this therapeutic good, AbbVie Pty Ltd, is responsible for ensuring that the drug meets all regulatory standards and requirements for its designated use. Under the Therapeutic Goods Act and the Regulations, the designation of Andepatuzumab mafodotin as an orphan drug imposes specific obligations on the parties involved. The sponsor, AbbVie Pty Ltd, must ensure that the drug is manufactured, stored, and distributed in compliance with the standards set forth in the Act and the Regulations. This includes maintaining the quality and safety of the drug, providing accurate information about its use and potential side effects, and ensuring that it is used in accordance with its approved indications. Failure to comply with the obligations and requirements imposed by the Therapeutic Goods Act and the Regulations can result in serious consequences. The Act and the Regulations provide for both civil and criminal penalties for breaches. Civil penalties can include fines, with the exact amount determined by the court, while criminal penalties can include imprisonment. For example, under section 33D(3) of the Act, a person who is reckless in relation to the supply of a therapeutic good can be fined up to $222,200 for a corporation, or $44,440 for an individual. Additionally, under section 33E, a person who knowingly makes a false or misleading representation in relation to a therapeutic good can be fined up to $222,200 for a corporation, or $44,440 for an individual, or both. These penalties underscore the importance of compliance with the legislative and regulatory requirements governing the use and supply of therapeutic goods in Australia.